CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Chardan’s 7th Annual Genetic Medicines Conference
Fireside Chat: Monday, October 2, 2023 at 4:00 pm ET
Location: The Westin New York Grand Central, New York, NY
A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.
JonesTrading 2023 Healthcare Summit
October 10-11, 2023
Location: Eden Rock Miami Beach, Miami, FL
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.56 |
| Daily Change: | -0.08 -4.60 |
| Daily Volume: | 692,904 |
| Market Cap: | US$193.660M |
January 08, 2025 December 27, 2024 September 05, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
